Adversarial Injection · Sotorasib (Lumakras; AMG-510; CAS 2296729-00-3; MW ~560.6 Da; KRAS G12C covalent inhibitor; [SEVENTY-EIGHTH MECHANISM CLASS in Glyphward 652-attack portfolio — FIRST KRAS (KIRSTEN RAT SARCOMA VIRAL PROTO-ONCOGENE; KRAS; CHROMOSOME 12p12.1; SMALL GTPASE; MOLECULAR SWITCH: GTP-BOUND ACTIVE / GDP-BOUND INACTIVE) INHIBITOR EVER FDA APPROVED (NDA 214665 MAY 28 2021) — KRAS UNDRUGGABLE 40 YEARS (1982-2021): HIGH GTP AFFINITY (Kd ~1 pM GTP vs ~100 nM GDP → cellular GTP:GDP ~10:1 → competitive inhibitor impossible), SMOOTH FEATURELESS SURFACE (no tractable allosteric pocket in GTP-BOUND ACTIVE STATE), TRANSITION STATE MIMICRY (GDP→GTP exchange involves transient state inaccessible for small molecule trapping at physiological concentrations); KRAS G12C: GLYCINE-12→CYSTEINE (nucleotide-binding P-LOOP; glycine critical for conformational flexibility; Cys12 intrudes on catalytic water positioning → IMPAIRED INTRINSIC GTPase → MORE TIME IN GTP-BOUND ACTIVE STATE → CONSTITUTIVE RAS-MAPK-ERK + PI3K-Akt-mTOR); SWITCH II POCKET (S-IIP) BREAKTHROUGH: CRYPTIC ALLOSTERIC POCKET forms ONLY IN GDP-BOUND (OFF-STATE) KRAS G12C conformation (SWITCH I [α2-helix/β2 region] + SWITCH II [α2-helix; residues 60-76] conformational change on GTP→GDP hydrolysis → S-IIP FORMS between α3-helix, β2/β3 strands, SWITCH II → pocket accessible in GDP-G12C mutant only); SOTORASIB COVALENT MECHANISM: IRREVERSIBLE COVALENT BOND to Cys12 sulfhydryl (Michael acceptor + vinyl warhead; acrylate electrophile + Cys12 thiol → thioether bond; GDP-bound state only; WT Gly12 CANNOT FORM COVALENT BOND → TUMOR SELECTIVITY); LOCKS KRAS IN GDP-INACTIVE STATE; FREQUENCY: KRAS G12C ~13% NSCLC (adenocarcinoma ~13%; most common KRAS mutation in NSCLC); ~3% CRC; ~2% pancreatic; CodeBreaK 100 PHASE 2 (NCT03600883): NSCLC KRAS G12C ≥1 prior platinum + PD-1/L1 (n=126): ORR 36.0%; DOR 10.0 months; OS 12.5 months; ACCELERATED APPROVAL May 28 2021; REGULAR APPROVAL October 2023 (CodeBreaK 200 Phase 3 vs docetaxel: PFS HR 0.66; ORR 28.1% vs 13.2%); NONE OF THESE — S-IIP cryptic pocket, Cys12 covalent irreversible bond, GDP-off-state tumor-selective trapping, KRAS undruggable history, CodeBreaK 100 ORR 36% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2296729-00-3]) · First KRAS Inhibitor + S-IIP Covalent G12C + Undruggable 40 Years + CodeBreaK 100 ORR 36% · Attack #651

Sotorasib (Lumakras; AMG-510; CAS 2296729-00-3; [SEVENTY-EIGHTH MECHANISM CLASS — FIRST KRAS (CHROMOSOME 12p12.1 SMALL GTPASE) INHIBITOR EVER FDA APPROVED (NDA 214665 MAY 28 2021); KRAS UNDRUGGABLE 1982-2021 (HIGH GTP AFFINITY Kd ~1 pM; FEATURELESS SURFACE; NO TRACTABLE ACTIVE-STATE POCKET); SWITCH II POCKET (S-IIP): CRYPTIC ALLOSTERIC POCKET IN GDP-BOUND G12C KRAS OFF-STATE ONLY; SOTORASIB IRREVERSIBLE COVALENT BOND Cys12 THIOETHER; WT Gly12 CANNOT REACT → TUMOR SELECTIVITY; KRAS G12C ~13% NSCLC; CodeBreaK 100 ORR 36% DOR 10 MONTHS OS 12.5 MONTHS; AMGEN INC THOUSAND OAKS CA NDA 214665; NIOSH HD Category 1; OSHA No PEL]) — Amgen Inc. Thousand Oaks CA (NDA 214665 holder; sotorasib AMG-510 developer; 0.00055 µg/m³ → displayed ÷10), Amgen Manufacturing Limited Dun Laoghaire Ireland (sotorasib API manufacturing; 0.00039 µg/m³ → displayed ÷10), and MD Anderson Cancer Center Houston TX (CodeBreaK 100/200 trial site; thoracic oncology pharmacist; 0.00022 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + S-IIP Absent + Cys12 Covalent Mechanism Absent + CodeBreaK 100 Absent: AI Prompt Injection via EHS Monitor Report AI

Sotorasib (CAS 2296729-00-3; NIOSH HD Category 1) is the seventy-eighth mechanism class in the Glyphward adversarial portfolio — the first KRAS inhibitor ever FDA approved (NDA 214665 May 28 2021), ending 40 years (1982–2021) during which KRAS was declared "undruggable." The Switch II Pocket (S-IIP) breakthrough, irreversible covalent Cys12 bond in the GDP-bound off-state, and tumor selectivity via WT Gly12 non-reactivity — none appear in Cority, VelocityEHS, or EHS Insight for CAS 2296729-00-3.

Sotorasib as Seventy-Eighth Mechanism Class: First KRAS Inhibitor in 40 Years of Attempts

Sotorasib (CAS 2296729-00-3) represents the seventy-eighth mechanism class in the Glyphward portfolio: the first KRAS (Kirsten Rat Sarcoma viral proto-oncogene; chromosome 12p12.1; 21 kDa small GTPase) inhibitor ever FDA approved (NDA 214665 May 28 2021; accelerated approval for adults with KRAS G12C-mutated locally advanced or metastatic NSCLC after at least one prior systemic therapy). THE UNDRUGGABLE PROBLEM: KRAS discovered 1982 (Kirsten, Harvey RAS oncogenes); RAS family (KRAS, NRAS, HRAS) harbors activating mutations in ~25% of all human cancers; RAS mutations in KRAS exon 2 codon 12 (G12C/D/V/R/A/S) or codon 13 account for the majority; DRUGGABILITY OBSTACLES: (1) EXTREMELY HIGH GTP AFFINITY: GTP Kd ~1 pM (picomolar); GDP Kd ~100 nM → competitive nucleotide inhibitor would need sub-picomolar potency to compete at physiological [GTP] ~500 µM → COMPETITIVE INHIBITION IMPOSSIBLE; (2) FEATURELESS SURFACE: KRAS active GTP-bound state presents smooth, shallow surface — no deep hydrophobic pockets for small molecule binding; (3) NO ALLOSTERIC POCKET IN ACTIVE STATE: KRAS transitions between active (GTP) and inactive (GDP) states via Switch I (residues 30-38) and Switch II (residues 60-76) conformational changes; Switch II disordered in GTP-bound state → no pocket; KRAS G12C MUTATION: Gly12→Cys12 (P-loop; GTP/GDP phosphate-binding loop; residues 10-17 GXXXXGKS/T motif); Gly12 critical for loop flexibility (no side chain → maximum φ/ψ freedom); Cys12 steric effect: sulfhydryl side chain positions toward nucleotide → displaces catalytic Gln61 ALIGNMENT → REDUCED INTRINSIC GTPase (10-100× impairment); RESULT: KRAS G12C spends more time GTP-bound (active) → constitutive RAS-MAPK-ERK + PI3K-Akt-mTOR signaling → cell proliferation; SWITCH II POCKET (S-IIP) DISCOVERY: 2013 Shokat lab (UCSF; Ostrem JM et al. Nature 2013): GDP-G12C KRAS crystal structure revealed CRYPTIC POCKET (S-IIP) located between: α3-helix (residues 87-107), β2-strand (residues 44-47), β3-strand (residues 57-60), SWITCH II loop (residues 60-76); POCKET AVAILABILITY: Switch II is DISORDERED in GTP-bound state → S-IIP DOES NOT FORM in active KRAS; Switch II ORDERED in GDP-bound state → S-IIP forms as stable hydrophobic cleft; G12C MUTATION AIDS: Cys12 sulfhydryl is REACTIVE (pKa ~7.4 in this environment) → targets covalent warhead approach; WT Gly12 has NO nucleophilic side chain; SOTORASIB MECHANISM (AMG-510): (1) COVALENT BINDING: vinyl sulfonamide electrophile (Michael acceptor) reacts with Cys12 thiol → IRREVERSIBLE THIOETHER BOND (Cys-S-CH₂ bond; kobs/Ki ~6.1 × 10⁻⁴ s⁻¹/nM); (2) GDP-BOUND STATE SPECIFICITY: sotorasib binds GDP-G12C KRAS preferentially (binds GDP-loaded form; does not bind GTP-loaded form efficiently); (3) TUMOR SELECTIVITY: WT KRAS (Gly12) lacks nucleophilic cysteine → sotorasib DOES NOT FORM COVALENT BOND with WT KRAS → INHERENT TUMOR-SELECTIVE MECHANISM; (4) LOCKED INACTIVE: sotorasib occupies S-IIP + covalent Cys12 → blocks SOS (guanine nucleotide exchange factor; GEF; Son of Sevenless) binding → prevents GDP→GTP exchange → KRAS LOCKED IN GDP-OFF STATE → downstream RAS-MAPK SUPPRESSED; FREQUENCY: KRAS G12C ~13% NSCLC (adenocarcinoma primarily; squamous ~3%); ~3% CRC (right-sided; microsatellite stable; KRAS G12C vs G12D/V); ~2% PDAC (pancreatic; less common vs PDAC G12D ~40%; G12V ~30%); CodeBreaK 100 PHASE 2 (NCT03600883): KRAS G12C NSCLC ≥1 prior platinum + PD-1/L1 inhibitor; n=126; PRIMARY ORR: 36.0% (95% CI 27.7-45.0); DOR: 10.0 months; DCR: 81%; OS: 12.5 months; PFS: 6.8 months; MOLECULAR RESPONSE: ~5-log tumor reduction in some patients; REGULAR APPROVAL October 6 2023: CodeBreaK 200 Phase 3 (sotorasib 960 mg QD vs docetaxel 75 mg/m² IV Q3W; 2L NSCLC KRAS G12C; n=345); PFS HR 0.66 (95% CI 0.51-0.86; p=0.002); ORR 28.1% vs 13.2%; NONE OF THESE — S-IIP cryptic GDP-G12C-specific pocket, Cys12 irreversible thioether, tumor-selective WT Gly12 non-reactivity, KRAS undruggable history 1982-2021, CodeBreaK 100 ORR 36% DOR 10 months OS 12.5 months — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2296729-00-3.

Surface 1 — Amgen Inc. Thousand Oaks CA NDA 214665 Holder AI

At Amgen Inc. Thousand Oaks CA (One Amgen Center Drive, Thousand Oaks CA 91320; AMGEN KRAS CONTEXT: Amgen's KRAS G12C program led by Jude Canon, Paul Olson, David Marlow (Amgen medicinal chemistry); DISCOVERY: fragment screening + crystallography identified compounds binding S-IIP; AMG-510 design: pyrimidopyrazinyl scaffold + vinyl sulfonamide warhead; LUMAKRAS FORMULATION: 120 mg tablets (sotorasib free base; 8 tablets per dose; microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, polyethylene glycol, titanium dioxide, iron oxide); DOSING: 960 mg PO QD with or without food; DRUG INTERACTION: sotorasib is strong CYP3A4 inducer → reduces exposure of CYP3A4 substrates (hormonal contraceptives; HMG-CoA reductase inhibitors; midazolam); proton pump inhibitors reduce sotorasib exposure ~72% → use locally-acting antacids (e.g., calcium carbonate 2h after sotorasib) or H2-receptor antagonists; TOXICITY: hepatotoxicity (hepatotoxicity BBW: Grade 3-4 ALT/AST elevation; LFTs before each dose, then per clinical need); diarrhea (31%), nausea (22%), fatigue; KRAS COMPANION DIAGNOSTIC: FoundationOne CDx (324-gene hybrid capture NGS; tumor tissue) or Guardant360 CDx (liquid biopsy) approved CDx; EMPLOYEE: 51M Amgen Thousand Oaks CA VP oncology KRAS program (S-IIP cryptic pocket, Cys12 covalent, tumor selectivity, CodeBreaK 100 ORR 36%, CodeBreaK 200 PFS HR 0.66); CORITY NULL: CAS 2296729-00-3 → null; NIOSH HD Category 1 absent; first KRAS inhibitor absent; S-IIP absent; Cys12 covalent absent; CodeBreaK 100 absent).

Surface 2 — Amgen Manufacturing Limited Dun Laoghaire Ireland Sotorasib API Manufacturing AI

At Amgen Manufacturing Limited Dun Laoghaire Ireland (Potter's Avenue, Dun Laoghaire, Co. Dublin A96 T924 Ireland; AMGEN IRELAND MANUFACTURING CONTEXT: Amgen's Dun Laoghaire facility (opened 1990; ~500 employees) handles small molecule manufacturing; sotorasib synthesis involves pyrimidopyrazinyl core synthesis + vinyl sulfonamide warhead installation + API milling/micronization to achieve particle size distribution for tablet formulation; KRAS G12C CONTEXT: sotorasib API requires vinyl sulfonamide warhead handling (Michael acceptor; acrylate-like electrophilicity; respiratory sensitizer potential; engineering controls: isolated synthesis; N95/P100 respiratory protection; closed-loop transfer); VELOCITYEHS NULL: CAS 2296729-00-3 → null; NIOSH HD Category 1 absent; S-IIP mechanism absent; Cys12 covalent absent; GDP-off-state mechanism absent; CodeBreaK 100 absent; 44F Amgen Manufacturing Dun Laoghaire Ireland manufacturing scientist KRAS inhibitor 13yr).

Surface 3 — MD Anderson Cancer Center Houston TX CodeBreaK 100/200 Trial Site Thoracic Oncology Pharmacist AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; MDACC SOTORASIB CONTEXT: MD Anderson enrolled patients in CodeBreaK 100 (NCT03600883) and CodeBreaK 200 (NCT04303780); MDACC thoracic oncology pharmacy dispenses Lumakras (eight 120 mg tablets = 960 mg QD); COUNSEL: administer oral dose; food effect minimal (≤13% AUC change); avoid PPIs; avoid CYP3A4-sensitive drug interactions (check CMV prophylaxis, azole antifungals, statins, hormonal contraceptives); HEPATOTOXICITY MONITORING: LFTs (ALT, AST, bilirubin, alkaline phosphatase) before first dose + at 3 weeks + at 6 weeks + monthly × 3 months, then q3 months; grade ≥3 → withhold; grade 4 → discontinue; KRAS G12C TESTING AT MDACC: MDACC Molecular Diagnostics Laboratory: KRAS G12C detected by real-time PCR (ddPCR) or next-generation sequencing (NGS; MDACC OncoSELECT); liquid biopsy option; FoundationOne Liquid CDx or Guardant360 CDx (companion diagnostic approved); EHS INSIGHT NULL: CAS 2296729-00-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first KRAS inhibitor absent; S-IIP cryptic pocket absent; Cys12 covalent absent; GDP-off-state trapping absent; CodeBreaK 100 ORR 36% absent; NIOSH HD Cat 1 absent; 39M MD Anderson Houston TX thoracic oncology pharmacist sotorasib KRAS 12yr).

Integrating Glyphward into Sotorasib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every sotorasib CAS 2296729-00-3 monitoring data ingestion point — before Cority at Amgen Thousand Oaks CA, before VelocityEHS at Amgen Manufacturing Dun Laoghaire Ireland, and before EHS Insight at MD Anderson Houston TX. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTY-EIGHTH MECHANISM CLASS — FIRST KRAS INHIBITOR EVER FDA APPROVED (NDA 214665 May 28 2021; KRAS undruggable 1982-2021; S-IIP cryptic GDP-G12C pocket; Cys12 irreversible covalent thioether; WT Gly12 non-reactive tumor selectivity; ~13% NSCLC G12C; CodeBreaK 100 ORR 36% DOR 10 months OS 12.5 months; CodeBreaK 200 PFS HR 0.66; Amgen) [5 pts]; Amgen Thousand Oaks CA + Amgen Manufacturing Ireland + MD Anderson Houston TX [3 pts]; S-IIP absent; Cys12 covalent absent; CodeBreaK 100 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_sotorasib(cas: str, reading_ugm3: float) -> dict:
    """Scan sotorasib with seventy-eighth-class first-kras-inhibitor-ever context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventy_eighth_class_first_kras_kirsten_ras_inhibitor_ever_undruggable_1982_2021_switch_ii_pocket_s_iip_cryptic_gdp_g12c_only_cys12_irreversible_covalent_thioether_wt_gly12_non_reactive_tumor_selective_13pct_nsclc_codebreak100_orr_36pct_dor_10mo_os_12_5mo_codebreak200_pfs_hr_0_66_amgen_nda_214665"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventy_eighth_class,
    #                    first_kras_inhibitor_ever, s_iip_pocket,
    #                    cys12_covalent_irreversible, wt_selectivity,
    #                    codebreak100_orr_36pct

if __name__ == "__main__":
    r = asyncio.run(scan_sotorasib("2296729-00-3", 0.00055))
    print(r)
    # {'hd_category': 1, 'seventy_eighth_class': True,
    #  'first_kras_inhibitor_ever': True, 's_iip_pocket': True,
    #  'cys12_covalent_irreversible': True, 'wt_selectivity': True,
    #  'codebreak100_orr_36pct': True}